Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)

Anders Bruun Mathiasen; Erik Jørgensen; Abbas Ali Qayyum; Mandana Haack-Sørensen; Annette Ekblond; Jens Kastrup

doi:10.1016/j.ahj.2012.05.026

Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)

Anders Bruun Mathiasen, Erik Jørgensen, Abbas Ali Qayyum, Mandana Haack-Sørensen, Annette Ekblond, Jens Kastrup

78 Citations (Scopus)

Abstract

Stem cell therapy is an emerging treatment modality in cardiovascular disease. The best cell type and delivery method in different cardiovascular diseases remain to be determined.

Original language	English
Journal	American Heart Journal
Volume	164
Issue number	3
Pages (from-to)	285-91
Number of pages	7
ISSN	0002-8703
DOIs	https://doi.org/10.1016/j.ahj.2012.05.026
Publication status	Published - 2012

Keywords

Bone Marrow Cells
Coronary Artery Disease
Double-Blind Method
Follow-Up Studies
Heart Failure
Humans
Injections
Magnetic Resonance Imaging
Mesenchymal Stem Cell Transplantation
Research Design
Stroke Volume
Systole
Tomography, X-Ray Computed
Transplantation, Autologous
Treatment Outcome
Ventricular Function, Left

Access to Document

10.1016/j.ahj.2012.05.026

Fingerprint

Dive into the research topics of 'Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)'. Together they form a unique fingerprint.

Cite this

Mathiasen, A. B., Jørgensen, E., Qayyum, A. A., Haack-Sørensen, M., Ekblond, A., & Kastrup, J. (2012). Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). American Heart Journal, 164(3), 285-91. https://doi.org/10.1016/j.ahj.2012.05.026

Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). / Mathiasen, Anders Bruun ; Jørgensen, Erik; Qayyum, Abbas Ali et al.
In: American Heart Journal, Vol. 164, No. 3, 2012, p. 285-91.

Research output: Contribution to journal › Journal article › Research › peer-review

Mathiasen, AB , Jørgensen, E, Qayyum, AA, Haack-Sørensen, M, Ekblond, A & Kastrup, J 2012, 'Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)', American Heart Journal, vol. 164, no. 3, pp. 285-91. https://doi.org/10.1016/j.ahj.2012.05.026

Mathiasen AB , Jørgensen E, Qayyum AA, Haack-Sørensen M, Ekblond A, Kastrup J. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). American Heart Journal. 2012;164(3):285-91. doi: 10.1016/j.ahj.2012.05.026

@article{646a57d7fb654748aeb71c50b16340fa,

title = "Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)",

abstract = "Stem cell therapy is an emerging treatment modality in cardiovascular disease. The best cell type and delivery method in different cardiovascular diseases remain to be determined.",

keywords = "Bone Marrow Cells, Coronary Artery Disease, Double-Blind Method, Follow-Up Studies, Heart Failure, Humans, Injections, Magnetic Resonance Imaging, Mesenchymal Stem Cell Transplantation, Research Design, Stroke Volume, Systole, Tomography, X-Ray Computed, Transplantation, Autologous, Treatment Outcome, Ventricular Function, Left",

author = "Mathiasen, {Anders Bruun} and Erik J{\o}rgensen and Qayyum, {Abbas Ali} and Mandana Haack-S{\o}rensen and Annette Ekblond and Jens Kastrup",

year = "2012",

doi = "10.1016/j.ahj.2012.05.026",

language = "English",

volume = "164",

pages = "285--91",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby, Inc",

number = "3",

}

TY - JOUR

T1 - Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)

AU - Mathiasen, Anders Bruun

AU - Jørgensen, Erik

AU - Qayyum, Abbas Ali

AU - Haack-Sørensen, Mandana

AU - Ekblond, Annette

AU - Kastrup, Jens

PY - 2012

Y1 - 2012

N2 - Stem cell therapy is an emerging treatment modality in cardiovascular disease. The best cell type and delivery method in different cardiovascular diseases remain to be determined.

AB - Stem cell therapy is an emerging treatment modality in cardiovascular disease. The best cell type and delivery method in different cardiovascular diseases remain to be determined.

KW - Bone Marrow Cells

KW - Coronary Artery Disease

KW - Double-Blind Method

KW - Follow-Up Studies

KW - Heart Failure

KW - Humans

KW - Injections

KW - Magnetic Resonance Imaging

KW - Mesenchymal Stem Cell Transplantation

KW - Research Design

KW - Stroke Volume

KW - Systole

KW - Tomography, X-Ray Computed

KW - Transplantation, Autologous

KW - Treatment Outcome

KW - Ventricular Function, Left

U2 - 10.1016/j.ahj.2012.05.026

DO - 10.1016/j.ahj.2012.05.026

M3 - Journal article

C2 - 22980293

SN - 0002-8703

VL - 164

SP - 285

EP - 291

JO - American Heart Journal

JF - American Heart Journal

IS - 3

ER -